Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
PLOS One · 2025
DOI: 10.1371/journal.pone.0321356 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Matteo Domenico Marsiglia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Università degli Studi di Milano, Milano, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, RNA, Viral, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe disease and deaths. This study evaluates real-life data on the effectiveness of mAbs therapies against SARS-CoV-2 infections by different viral variants, particularly in the presence of RNAemia, focusing on clinical outcomes.
Methods
From March 2021 to May 2022, high-risk patients with PCR-confirmed mild-moderate COVID-19 were enrolled at the Clinic of Infectious Diseases, San Paolo Hospital in Milan. Patients received Bamlanivimab/Bamlanivimab + Etesevimab/Casirivimab + Imdevimab/Sotrovimab based on Agenzia Italiana del Farmaco (AIFA) guidelines and prevalent SARS-CoV-2 variants. Nasopharyngeal swabs (NPS) and plasma samples were collected at infusion (t0) and after 7 days (t1). NPS viral loads and RNAemia were quantified using RT-qPCR, and variant typing was conducted. Clinical outcomes were evaluated, including time to symptom resolution and adverse effects.
Results
Among 176 enrolled patients, treatment efficacy was observed in 96.6% with a median time to symptom resolution of 12 days (IQR 10–19). Viral load significantly decreased in both NPS and plasma by day 7 post-treatment (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.
- Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Milano, Italy.
ORCID-Profile: Matteo Domenico Marsiglia, Silvia Bianchi, Francesca Bai, Camilla Tincati, Emerenziana Ottaviano, Silvia Ancona, Giulia Marchetti, Elisa Borghi
Zitieren
APA
Marsiglia, M. D., Bianchi, S., Bai, F., Tincati, C., Ottaviano, E., Ancona, S., Marchetti, G., & Borghi, E. (2025). Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients. PLOS One. https://doi.org/10.1371/journal.pone.0321356
Vancouver
Marsiglia MD, Bianchi S, Bai F, Tincati C, Ottaviano E, Ancona S, et al. Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients. PLOS One. 2025. doi:10.1371/journal.pone.0321356
BibTeX
@article{Marsiglia2025,
author = {Marsiglia, Matteo Domenico and Bianchi, Silvia and Bai, Francesca and Tincati, Camilla and Ottaviano, Emerenziana and Ancona, Silvia and Marchetti, Giulia and Borghi, Elisa},
title = {Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321356}
}
EUVIMED